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Chapter 11 
OVARIAN TUMORS IN CHILDREN 
AND ADOLESCENTS 
Linah Al-Alem, MSc, Amit M. Deokar, MD, MPH, 
Rebecca Timme, MD and Hatim A Omar* MD 
Adolescent Medicine and Young Parent Programs, J422 Kentucky 
Clinic, Department of Pediatrics, Kentucky Children's Hospital, 
University of Kentucky College of Medicine, Lexington, Kentucky, 
United States of America 
Ovarian tumors are uncommon in the child and adolescent 
population, but given that cancer is a leading cause of death even in 
this age group it is important for the general practice physician to be 
aware of the signs and symptoms. These can include abdominal 
pain, increased abdominal girth, a palpable mass on pelvic or 
abdominal exam, nausea and vomiting, decreased appetite, weight 
loss. constipation. back pain, leg cramps, dyspareunia, urinary 
symptoms, abnormal uterine bleeding, and ascites, to name a few . 
* Correspondence; Professor Hatim A Omar, MD. PAAP, 
Director of Adolescent Medicine and Young Parent programs, J422 Kentucky Clinic, 
Department of Pediatrics, Kentucky Children's Hospital, University of Kentucky  
College of Medicine, 
Lexington, KY 40536 United States. 
Tel: 859-323-6426 ext. 311: Fax. 859-257-7706; E-mail: haomar2@uky.edu 
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The types of gynecological tumors seen in adults are also seen in 
children except in differing frequencies. The most common type of 
ovarian tumor in children is the germ cell tumor, of which there are 
several subtypes including dem1oid cysts, dysgerminoma, yolk sac 
tumor, immature teratomas, and embryonal carcinomas.  
INTRODUCTION 
Ovarian tumors in children and adolescents are the most common genital 
neoplasms ( 1 ) .  In fact, ovarian rumors account for 1 % of all neoplasms in 
girls under the age of 17 (1) and although ovarian tumors are relatively 
rare, they comprise about 70% of all childhood gynecological 
malignancies (2). Overall, ovarian cancer claims the lives of 8.8 women 
per 100,000 women in the total population (3). Ovarian tumors are 
diverse in origin, progression and treatment. All types of ovarian tumors 
that are seen in adults are also seen in children but their incidence is 
different ( 4). The most common types of ovarian tumors in adolescents 
are the functional non-neoplastic types and germ cell tumors (4,5). This 
is different from the adult population, where the majority of neoplasms 
are ovarian epithelial tumors (6,7). In addition, only 10% of the ovarian 
tumors occurring in adolescents are actually malignant (8). Nevertheless, 
cancer is a leading cause of death in the adolescent age group, after 
accidents and injuries, homicides and suicides (8). History taking and 
physical examination are the hallmarks of ovarian tumor diagnosis and 
treatment in the adolescent population. This is of extreme importance in 
order to ensure a healthy future (4). Unfortunately, ovarian neoplasm 
diagnosis is still a problem in today's clinics due to the vague symptoms 
with which the patient presents (3). This chapter aims to discuss the 
different ovarian tumors as well as their management focusing on the 
pediatric and adolescent population.  
TYPES OF OVARIAN TUMORS 
'There are six main categories of primary ovarian tumors, namely: 
Functional cysts, benign ovarian tumors, borderline tumors, neoplasms of 
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germ cell origin (germ cell tumors), celomic (epithelial) origin tumors 
(epithelial ovarian cancer) and virilizing tumors. This classification is 
based on the present day concept of development and structure of the 
ovary (9). Other organizations, such as the WHO (World Health 
Organization), classify ovarian neoplasms into nine main categories and 26 
subtypes. In this chapter we will be discussing the major six types of 
ovarian tumors that may be seen by the primary care provider. Usually 
after the primary finding of a tumor., the patient is usually referred to a 
gynecologic oncologist (1).  
EPIDEMIOLOGY 
The incidence o f  gonadal tumors in general increases with the onset of 
puberty. The incidence of all germ cell tumors, the most common type of 
ovarian tumors in children, is about 0.6-0.9 per 100,000 children. It is 
worthy to note that 25% of all pediatric germ cell tumors present as 
tumors with more than one histological type (10). Nevertheless, this 
varies significantly according to sex and age. As for the incidence of 
ovarian cancer, it tends to rise with age peaking in the eighth decade, and 
therefore rarely seen in the adolescent population (10). The majority of 
ovarian cancers are the result of sporadic mutations; approximately 10% 
are attributed to familial disposition. Females carrying deletions in the 
BRCA 1 and BRCA2 genes (tumor suppressor genes) make up the largest 
subset risk for ovarian cancer. These deletions are inherited in an 
autosomal dominant mode (10). Focusing on 76 subjects under 20 years 
of age with ovarian neoplasm, one report found that 63% had germ cell 
etiology (11). Thus, although the general incidence of ovarian tumors in 
the adolescent population is low, it does occur and early diagnosis is vital 
to ensure better survival as well as a better quality of life. What follows 
is a discussion of the 6 different subtypes of ovarian tumors. 
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CLINICAL PRESENTATIONS 
It is of vital importance that primary care providers are aware of the 
different ways in which children and adolescents can present clinically. 
In contrast, older women may be asymptomatic. The symptoms of an 
individual ovarian mass are mentioned in the respective sections. Below 
is a list of symptoms that may mimic conditions such as appendicitis, 
urinary tract infections, gastroenteritis, sexually transmitted disease and 
constipation (12). This list of symptoms will help the provider decrease 
the probability of misdiagnosing ovarian tumor. They include the 
following:  
1. Abdominal pain
This is a fairly consistent symptom in girls under the age of 10 years 
(13). It also is the main complaint in all adolescents (14). Occasionally 
there may be pressure symptoms in the abdomen or pelvis. Localization 
of the pain may depend largely on the age and development of the girl 
and is generally higher in the abdominal area due to the relative superior 
location of the ovary in young girls. Some children can present with an 
acute abdomen and surgical exploration is warranted in cases of adnexal 
torsion. Imaging is often helpful in aiding and confirming the 
diagnosis(15). It is very crucial for the provider to be aware of other 
acu1e situations such as appendicitis, but at the same time remember that 
ovary-related pain may mimic such presentation(12). 
2. Increased abdominal girth and palpable mass
This could be fixed or nodular. The mass could also be bilateral (14-16). 
Palpating the mass can be challenging in an overweight individual. 
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3. Other symptoms includes (12-15):
• Nausea and vomiting
• Decreased appetite 
• Loss of weight
• Constipation
• Back pain 
• Leg cramps
• Isosexual precocious pseudopuberty (15)
• Dyspareunia
• Urinary symptoms such as, urgency, dysuria, etc.
• Menstrual abnormalities like abnormal uterine bleeding (AUB),
amenorrhea/oligomenorrhea, menorrhagia, and dysmenorrhea 
• Ascites
• Hydrothorax and difficulty breathing 
• Virilization
4. Rare presentation(s):
• Thrombocytosis. especially with malignant tumors (17)
• Extranodal non-Hodgkin's lymphoma may present as an ovarian 
mass (18)
A.OVARIAN FUNCTIONAL CYSTS
Ovarian functional cysts are also known as benign cysts, simple cysts or 
physiological cysts. Functional cysts as well as benign neoplasms 
(discussed later on) are the most common ovarian masses among young 
adolescents (19). The etiology of functional cysts changes with each 
stage of development due to hormonal changes (20). In general, 
functional ovarian cysts arc mostly non-neoplastic in nature and can be 
of a follicular, luteal or pregnancy-related luteoma. A functional cyst 
usually occurs in about 7 .8% of reproductive aged women (9) and are the 
most common lesions in the pediatric age range (21). Functional cysts 
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occur due to an exaggerated cyclic ovarian function. Thus, most 
functional cysts resolve in a short period of time, usually within one or 
two cycles or put differently, 6 to 10 weeks (9) without treatment (20). If 
the cyst persists, the diagnosis should remain in question as potentially 
neoplastic in nature particularly if the patient has symptoms (20). Some 
reports consider lesions that are more than 10 cm as potentially 
neoplastic, while those that are less than 5 cm as non-neoplastic (9). It 
should be noted that all functional cyst subtypes are usually benign (22). 
Ovarian functional cysts are usually unilateral but may occur bilaterally 
(1). 
Risk factors 
The use of progestin only contraceptives may increase the risk of ovarian 
tumor development (9). But in general, the use of mixed (progestin and 
estrogen) oral contraceptives early acts as a protective agent against 
ovarian functional cysts (23). The development of functional cyst 
malignancies are more prominent in pre-pubertal girls especially if 
ascites is detected (9). Possible complications that may occur post cyst 
formation include cyst rupture, intracystic hemorrhage, ovarian torsion 
and necrosis (1). 
Subtypes of ovarian functional cysts 
Follicular origin 
These cysts form as a result  of  anovulation.  The foll icle starts 
accumulating cystic fluid, rendering it larger than 25-30 mm when 
inspected with an ultrasound. Cysts should only be named 'functional 
cysts' when they are 5-10 cm in size. This is due to the notion that 
follicles can normally reach 5 cm (9). Most of the time, functional cysts 
resolve on their own (20). 
Luteal origin 
These cyst  usually occur during the luteal phase. A patient may present 
to the clinic with severe acute pain, which may be due to a ruptured cyst. 
Ovarian Tumors in Children and Adolescents 603 
Ruptured cysts may cause intraperitoneal bleeding or an unruptured cyst
causing bleeding into the cyst cavity (hemorrhagic cyst). Functional cysts
of luteal origin appear sponge like upon ultra sound inspection. In  fact,
they may even be confused with the development of ectopic pregnancies
(9). Thus, when an ectopic pregnancy is suspected, functional cysts of
luteal origin should be eliminated. 
Pregnancy-related luteoma 
This subtype of functional cysts is rare and is often asymptomatic. It is
usually seen in adolescents that are pregnant and undergoing cesarean
deliveries. These cysts are usually larger than 20 cm in diameter. In 50%
of the cases presenting with pregnancy-related luteoma, female fetal
masculinization is seen (9). 
Symptoms 
In general. functional cysts may cause acute pain, pressure, dull or achy
pain that is often present for several weeks especially when the cyst is
large, torsed or ruptured (9). It should also be noted that patients could be 
asymptomatic, particularly those that are of a pregnancy-related luteoma.
Other symptoms that the patient may present with are complaints of pain
during bowel movements or intercourse. In some cases, patients may
complains of changes in menstruation (Irregular, longer, or shorter
periods) (9). 
Diagnosis 
Ultrasonography is usually utilized to localize ovarian lesions but cannot
be used to determine whether these lesions are malignant or not (21).
Histological analysis is needed in order to determine the pathology of the
cyst. Thus, ultrasound is the most common imaging used in making a
functional cyst diagnosis, while MRI is rarely used (9). Pelvic exams are
also helpful in view of the fact that it might indicate a palpable mass. This
depends on the size of the cyst and the patient weight. An
abdominal exam may reveal tenderness or rebound (9). Several lab tests
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may be performed such as CA-125 (Cancer Anligen 125). It is important 
to note that CA 125 in adolescents may not help in distinguishing benign 
from malignant cysts and thus, although it may be helpful in some cases, 
it is not helpful in most cases. The most important lab test is human 
chorionic gonadotropin (?-HCG), which would indicate pregnancy but 
can be also be elevated in some tumors. In pregnancy-related lutcomas, 
testosterone and AFP (Alpha Feto Protein) can be elevated (9). 
Other conditions causing similar symptoms 
There are several medical conditions that usually present to the clinician 
with identical symptoms. These conditions should be eliminated before a 
functional cyst diagnosis is reached. These include conditions such as: 
PCOS (polycystic ovarian syndrome), endometriomas, ectopic 
pregnancies, appendicitis, other ovarian tumors (dermoid cysts, 
mucinous, serous cystadenomas, Fallopian tube carcinomas), PID (pelvic 
inflammatory disease) and hyperthecosis (9). 
Treatment 
Functional cysts tend to resolve on their own (20), and although oral 
contraceptive pills are often used, some state that combination oral 
contraceptives do not accelerate the regression of these cysts (9,23). In 
general, surgical procedures are not done unless absolutely necessary and 
should spare the ovary as much as possible (20). If functional cysts of 
follicular origin are the diagnosis, the follicle should be monitored for 1- 
2 cycles. Functional cysts should regress and become smaller with time 
and if they persist, surgery may be considered (9). If the patient presents 
with acute pain, the clinician should consider timing the pain with 
ultrasound images and characteristics to attempt to correlate the two. In 
addition, the clinician should consider the possibility of cystic rupture. 
Corpus luteum pain symptoms are usually treated with analgesics or 
narcotics although one should be careful with prescribing narcotic 
analgesics to adolescents for obvious reasons. This pain management 
would give the patient relief from the pain allowing the patient to be 
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monitored for 6 weeks. If after 6 weeks the cyst is enlarging or persistent 
then this might indicate malignancy of the cyst (9). Laparoscopy is the 
most common approach if the functional cyst is persistent (20). This 
approach is used in dermoid cysts, which will be discussed later (9). It 
should be noted that if the adolescent is pregnant, this will probably 
cause an added complexity in trying to differentiate between malignant 
and benign cysts (9). Surgery should be a voided as much as possible and 
is only used in enlarged or persistent cysts after a minimum of two cycles 
(9;23). Pregnancy luteomas have been shown to resolve on their own 
after delivery (9).  
Follow-up 
The rate of malignancy is very low in functional cysts (l). However, if 
malignancy is suspected, refe1Tal to an oncologist .is necessary. In order 
to prevent future functional cyst formation, oral contraceptives may be 
used. Regular pelvic exams are usually used to monitor patients but 
repeated ultrasound imaging is not usually indicated (9). 
B.  BENIGN OVARIAN TUMORS 
Benign ovarian masses are rare in the pediatric and adolescent population 
unless they are benign functional cysts. The incidence of benign tumors 
is not very accurate, but 2/3 of these benign tumors occur in 20-44 year 
old patients. Thus, the incidence in the pediatric and adolescent 
population is very low (9). Benign ovarian tumors are also known as 
ovarian cysts, tumor masses or adnexal masses. These tumors are often 
common in patients of reproductive age. Of all ovarian tumors, benign 
tumors account for 80-85%. The prognosis for benign ovarian tumors is 
often excellent. 
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Risk factors 
Smoking in the adolescent population increases the risk of developing 
benign ovarian tumors by about three fold. Another risk factor is obesity. 
In contrast, pregnancy is associated i1wersely to ovarian tumor 
development. It should be noted that the presence of a benign ovarian 
tumor serves as a risk factor for the development of ovarian cancer 
lacer in life (9). Hence, it is necessary to follow up patients into their 
adulthood or inform them of their future risk. 
Subtypes of benign ovarian tumors 
Functional cysts 
These usually do not require surgery and arc asymptomatic and  benign. 
Please refer to Function Ovarian cyst section for more information. 
Benign tumors do not have any  staging system. 
Endometriosis
These are also known as 'chocolate cysts' and often develop when the patient is 
diagnosed with endometriosis (9). 
Benign cystic teratomas 
These are also known as dermoid cysts and are considered benign germ 
cell tumors which are the most. common tumors in adolescents and in 
fact, account for about 60% of neoplasms in women under 40 years (9). 
Epithelial tumors 
There are two main types of epithelial ovarian tumors. These are: serous 
and mucinous. Other epithelial benign tumors include endometriod. 
clear cell, Brenner mixed epithelial and fibromas. Serous tumors are 
often benign but in 5-10% of the cases may present as borderline ovarian 
tumors and in 20-25% are malignant. Mucinous tumors in turn may 
become very large hut only 5-10% are malignant in nature. 
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Symptoms 
Ovarian tumors are usually asymptomatic but when symptoms are 
present they are often nonspecific, mimicking gastrointestinal complaints 
such as nausea, vomiting, bloating, constipation, and indigestion. In 
addition, urinary urgency, increased abdominal girth fatigue and weight 
loss or weight gain are also common. Ovarian torsion is sometimes seen 
when acute pain is a patients' chief complaint. Pelvic pain, menstrual 
irregularities 1nay be present as well. 
Diagnosis 
A detailed history should be taken in order to assess familial risk, A 
breast exam is necessary since a history or presence of breast cancer is a 
risk for the development of ovarian rumors. Abdominal exams should 
test for the presence of ascites, a palpable mass or hepatomegaly, which 
would suggest the presence of an ovarian tumor. A pelvic exam is 
usually used to detect the presence of pelvic tenderness. Also, a pelvic 
mass with a size larger than 8-10 cm would suggest the presence of a 
neoplasm. Benign tumor diagnosis is done after surgical biopsy of the 
tumor and a histological exam. Nevertheless, a benign tumor does nor 
usually lead to the accumulation of ascites nor peritoneal tumor studding. 
The precise basis and origin of ovarian epithelial tumors is still unknown 
(9). Ovarian torsion usually occurs in benign ovarian tumors but not 
malignant ones. There are several lab tests that can be performed to help 
rule out tumors. The most sensitive exams to detect ovarian tumors 
include: ultrasound, MRI, and CT. In contrast, the most specific exams 
that can be done include: Bimanual exams, MRI, PET scans (9). CA-125 
is rarely used in premenopausal conditions and is not helpful in benign 
cases. A serum beta·HCG should always be done in order to rule out 
pregnancy. 
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Other conditions causing similar symptoms 
Several other medical conditions may present in the clinic that have 
similar symptoms to the presence of ovarian rumors. These include 
PCOS, infections, ovarian malignancy, fallopian tube malignancy, 
functional cysts, and other gynecological conditions such as peritoneal 
cysts, uterine fibroid, and paraovarian cysts (9). 
Treatment 
Patients should undergo a period of 6-8 weeks of close monitoring if the 
results of ultrasound and MRI are benign. Surgery is only done as a last 
resort and several factors should be taken into consideration such as age, 
pain, and growth persistence over time. Surgery may be done in cases of 
ovarian torsion and masses that do not resolve over time. Oral 
contraceptives are used to inhibit ovulation and thus may help prevent 
the development of non-neoplastic. In the case of benign cystfo 
teratomas, a cystectomy may be done in order to remove the cyst but 
preserve the ovary. If there are solid masses, surgical approaches should 
be followed by pelvic washings to prevent the risks of tumor cell 
spreading. Pathological exams should be performed in order to determine 
whether the tumor is for sure benign or not. If the tumor biopsy shows 
the presence of borderline or malignant rumors, refer to a gynecological 
oncologist (9).  
Follow-up 
Patients should be monitored with regular pelvic exams and if there are 
any abnormalities, ultrasound imaging should be used (9). 
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C. BORDERLINE OVARIAN TUMORS
Most borderline tumors occur in women between the ages of 30 and 50 
years. Thus, borderline tumors are rare in adolescents. This type of 
ovarian tumor accounts for 15% of all ovarian malignancies and usually 
occurs 10-20 years prior to the development of ova rian cancer. 
Borderline ovarian tumors undergo a less aggressive course than 
malignant forms, although it should be noted that it has the potential to 
metastasize and reoccur after years of tumor-free status. Borderline 
ovarian tumors are also known as low malignant potential (LMP) tumors. 
Risk factors 
Unlike other ovarian tumors, borderline ovarian tumors are not affected 
by smoking, oral contraceptive use, nor BRCA-1 or BRCA-2 mutations. 
A family history of ovarian cancer also does not affect the risk of 
developing ovarian cancer. One major risk factor is nulliparity (9). 
Subtypes of borderline ovarian tumors 
About 65% of borderline ovarian tumors have a serous histological type 
while 30% are mucinous. The remaining 5% account for the remaining 
four subtypes: Endometrioid, clear cell, Brenner cell and mixed. Tumor 
cells can spread by various methods including implantation in the 
peritoneal cavity or by the lymph system to pelvic lymph nodes and 
eventually 10 other organs. Borderline ovarian tumors should be staged 
after excision using the International Federation of Gynecological 
Oncologists (FIGO). 
Stage 1: The tumor is confined to the ovaries 
1A: tumor growth is limited to one ovary without any malignant 
ascites 
1B: tumor growth is limited to two ovaries without any malignant 
ascites 
1C: tumor or stage 1A or 1B, but with ascites or ruptured capsules 
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Stage 2: The tumor has spread to the pelvis  
2A: metastasis to the fallopian tubes or uterus 
2B: both ovaries affected and extended to the pelvis 
2C: a tumor of stage 2A or 2B, but with ascites 
Stage 3: There are tumor seeds in the abdominal cavity or 
retroperitoneal lymph nodes 
3A: confined to the pelvis 
3B: metastasis to the peritoneal cavity but not >2cm mass 
3C: metastasis to the peritoneal cavity but >2cm mass 
Stage 4: Metastasis into other distant organs 
Symptoms 
Major patient complaints include abdominal pain, constipation, bloating, 
nausea, weight changes, decreased appetite, dysuria and irregular 
menses. 
Diagnosis 
Physical exams often reveal solid or fixed masses and ascites or palpable 
mass upon abdominal exam. A CA-125 test should not be used in 
Borderline ovarian tumors since it is sometimes elevated in benign 
conditions, especially in pre-menopausal women with diseases such as 
pelvic inflammatory disease, endometriosis and liver disease. In order to 
distinguish between malignant and benign tumors, pelvic ultrasound and 
CT scans are often used. The presence of persistent pelvic mass upon 
serial imaging sessions, a mass larger than 8 cm, solid components, 
increased vascularity and bilateral ovarian involvements indicate a 
possible malignant tumor rather than borderline ovarian tumor. 
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Other conditions causing similar symptoms 
Infections such as tubo-ovarian abscess may result in symptoms that 
mimic Borderline ovarian tumors. Benign, malignant and metastatic 
gynecological neoplasm also may be misdiagnosed as Borderline ovarian 
tumors. Other conditions include the presence of pelvic kidney (9). 
Treatment 
Treatments of Borderline ova1ian tumors involve surgical removal of all 
visible masses. Chemotherapy is rarely beneficial due to the 
decrease/slow growth rate of this type of tumor. Surgery is typically 
used for diagnosis and treatment in this type of ovarian tumor. After 
tumor excision, proper staging is required by a gynecologic oncologist in 
order to ensure that all the mass is removed. The best removal is a total 
hysterectomy, although this should be done with care and only when the 
patient does not desire fertility. If histological analysis shows that the 
Borderline ovarian tumor is of mucinous origin, an appendectomy should 
also be performed. This is necessary due to the possible concomitant 
involvement of the appendix with the development of mucinous tumors. 
In reoccurrcnce cases, additional surgical excisions are done (9). 
Follow-up 
If the tumor is confined to the ovary and the surgery was successful no 
further surgical interventions arc needed. The patient should be referred 
to a gynecologic oncologist for monitoring and to determine whether any 
other treatment would be helpful. There is a chance of reoccurrence, 
particularly after 10-15 years. Usually survival rates are about 99% for 
ovarian borderline tumors diagnosed at stage l or 2. Five and twenty year 
survival rares drop to 90% and 45%, respectively at later stages. Thus, 
diagnosis at earlier stages is essential. About 6% of the cases could 
develop into a low grade serous carcinoma. A physical exam and CA- 
125 is needed every three months for two years and imaging every six 
months for two years. 
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D.GERM CELL OVARIAN TUMORS
This type of ovarian tumor is the most common ovarian tumor in 
adolescents and young women (9, 24). The median age range is 16-20 
years old but may occur in patients who are much younger, in fact, as 
early as 6 years of age. Thus, one of the important factors to consider is 
the preservation of fertility. These tumors originate from the germ cells 
of the ovary. Germ cell tumors account for about 5-7% of all ovarian 
cancers(9), 20% of ovarian tumors (25), and account for >60% of tumors 
occurring in patients younger than 20 years of age. One-th.ird of the 
germ cell tumors diagnosed in patients younger than 20 years of age are 
malignant. The most common subtype is the benign cystic teratoma, also 
known as dermoid cyst. It is worthy to note that this type of ovarian 
tumor accounts for about 25% of all rumors in pregnancies. 
Risk factors 
This is the most common type of ovarian tumors in young women (9, 25). 
Subtypes of germ cell ovarian tumors 
Germ cell ovarian tumors have 5 different subtypes. 
Dermoid cyst (mature cystic teratomas) 
Most of these contain hair or sebaceous material, but may also contain 
substances derived from all three germ cell layers. These are usually 
benign, but may be squamous carcinomas in 1% of the cases. 
Dysgerminoma 
This subtype comprises about 50% of all germ cell tumors and therefore 
is the most common subtype of germ cell tumors. They also tend to form 
before the age of 30. They are usually unilateral but are bilateral in about 
15% of the cases (2). In this subtype, due to the presence of enlarged 
cells, there is an elevation in lactate dehydrogenase (LOH) (2)1evels and 
in 5% of the cases cells may produce HCG which may also be elevated 
(2, 9). An important aspect of dysgerminoma is that it has the highest 
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possibility of spreading to the peritoneal cavity and lymph nodes 
compared to other ovarian malignancies (2). There is a recurrence rate of 
about 17% after treatment(2). 
Yolk sac tumors (endodermal sinus tumors) 
This subtype accounts for 25% of germ cell rumors and is the second 
most common subtype of germ cell rumors (2). Upon microscopic 
examination, these tumors have a distinct reticular pattern and usually 
contain acid-schiff (PAS) positive hyaline bodies. As well as papillary 
structures. these cells usually contain and secrete AFP (alpha-fetoprotein) 
which may be measured in serum. The median age in which these tumors 
present is 19 (2). The most common symptoms that patients complain of 
are abdominal pain, fever, vaginal bleeding or an abdominal mass (2).  
Immature teratoma 
This is the third most common subtype and accounts for about 15-20% of 
all ovarian germ cell tumors (2). Similar to dermoid cysts, they contain 
substances derived from all three germ cell layers (9). The median age at 
presentation is 19. This type of rumor usually does not produce any 
tumor markers and are almost exclusively unilateral and are stage 1 at 
diagnosis (2). The survival rate is highly dependent on the stage of the 
disease. TI1ose with grade I have a survival rate of about 93% while those 
with stage ID have a survival rate of about 33%. The mode of treatment 
is adjuvant chemotherapy as well as surgery (2). 
Embryonic carcinomas and choriocarcinomas 
Embryonic carcinoma is very rare and is often confused with 
Endodermal sinus tumors. 1l1irtccn years is the median age of 
presentation and is usually unilateral (2). These tumors usually give a 
positive pregnancy test and in 60% of the cases show a hormonal profile 
that is consistent with precocious puberty in premenarcheal girls and 
abnormal vaginal bleeding in postmenarcheal girls. Choriocarcinomas 
are extremely rare and are also associated with an increased HCG level 
(2). These subtypes tend to produce HCG, rarely AFP and cause irregular 
uterine bleeding (9). The efficacy of treatment using adjuvant 
chemotherapy is not known due to the rarity of this tumor. The treatment 
regimen is thus usually identical to the Endodermal sinus tumors. 
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Juvenile granulosa cell tumors 
These tumors often occur in the first two decades of life and in 80% of 
the cases, they present with menstrual irregularity or isosexual precocity. 
These patients may present with peritonitis, ascites and/or a pelvic mass. 
The majority of these tumors are unilateral and thus limited unilateral 
salpingo-oophorectomy is usually sufficien1 to confine the disease and 
the patient would not require any further therapy. 
Germ cell ovarian tumors should be staged after excision using the 
International Federation of Gynecologic Oncologists (FIGO). 
Stage 1: tumor is confined to the ovaries 
IA: tumor growth is limited to one ovary without any malignant 
ascites 
I B: tumor growth is limited to two ovaries without any malignant 
ascites 
IC: tumor or stage 1A or 1 B but with ascites or ruptured capsules 
Stage 2: tumor has spread to the pelvis 
2A: metastasis to the fallopian tubes or uterus 
2B: both ovaries affected and extended to the pelvis 
2C: a tumor of stage 2A or 2B  But with ascites 
Stage 3: tumor seeds in the abdominal cavity or retroperitoneal 
lymph nodes 
3A: confined to the pelvis 
3B: metastasis to the peritoneal cavity but not >2cm mass 
3C: metastasis to the peritoneal cavity but >2cm mass 
Stage 4: metastasis into other distant organs 
Symptoms 
Patients usually present with acute abdominal pain which is likely due to 
ovarian torsion, hemorrhage or cyst rupture. There may be vaginal 
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bleeding, fever. as well as symptoms of hyperthyroidism or carcinoid 
syndrome. 
Diagnosis 
Diagnosis is done using CT of the abdomen and pelvis as well as an 
ultrasound. A physical exam is often used to detect an abdominal and 
pelvic mass. Primary amenorrhea, virilization and genital abnormalities 
should also be used as diagnostic events. HCG, AFP, CA-125 and LDH 
should be measured and monitored. 
Other conditions causing similar symptoms 
Germ cell ovarian tumors may present with symptoms that are also seen 
in appendicitis, ectopic pregnancy and ovarian torsion. Titus, these 
conditions should be eliminated prior to making a final diagnosis. 
Epithelial ovarian tumors, adrenal tumors and other pelvic masses may 
also be behind these symptoms. 
Treatment 
Due to fertility concerns, radiation is rarely used in germ cell tumors (9). 
These types of ovarian tumors are very chemosensitive to platinum-based 
therapies (25). Chemotherapy using bleomycin, etoposide, cisplatin (9, 
24), actinomycin D and vinc1iscine is sometimes used. Surgery is usually 
done in cases where a benign cystic teratoma is the diagnosis, as well as 
unilateral salpingo-oophorectomy (2). Staging after surgery is essential in 
determining what the next step is going to be (9). Dysgerminoma is 
treated by unilateral salpingo-oophorectomy making sure that a frozen 
section should be obtained, at the time of the laboratory. to confirm the 
diagnosis. 
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Follow-up 
If there is a significant mass or abnormal HCG, AFP or CA-125, the patient 
should be immediately referred to a gynecologic oncologist. Lymph node 
metastasis depend on the histological subtype of the tumor and is indicative of 
poor survival (25).  
E. MALIGNANT EPITHELIAL OVARIAN TUMORS
Epithelial ovarian cancer is the number one cause of gynecologjcal death 
in women and the fifth leading cause of death in women overall (10). 
Accounting for about 90% of ovarian cancers, epithelial ovarian tumors 
are the most common type of ovarian cancer (6). This type affects mostly 
postmenopausal women. The lifetime risk of developing ovarian cancer 
in the population is about 1.4%. Ovarian cancer is very rare in the 
adolescent age group. About 2.3% of ovarian cancers occur in patients 
under 25 years of age. out of which only about 40% were under 19 years 
of age (26). In general malignant neoplasms are very rare in the pediatric 
and adolescent population (21). 
Risk factors 
There are several risk factors for developing epithelial ovarian tumors 
including early menarche, late age of menopause. no children, infertility 
and talc use. Some of the protective factors against epithelial ovarian 
tumors include pregnancy, oral contraceptive use and breastfeeding. 
Subtypes of epithelial ovarian tumors 
All epithelial ovarian tumors should be removed and staged after 
excision using the International Federation of Gynecological Oncologists 
(FTGO). 
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Stage 1:  tumor is confined to the ovaries 
IA: tumor growth is limited to one ovary without any malignant 
ascites 
IB: tumor growth is limited to two ovaries without any malignant 
ascites 
LC: tumor or stage 1A or 1B but with ascites or ruptured capsules 
Stage 2: tumor has spread to the pelvis 
2A: metastasis to the fallopian tubes or uterus 
2B: both ovaries affected and extended to the pelvis 
2C: a tumor of stage 2A or 2B but with ascites 
Stage 3: tumor seeds in the  abdominal cavity or retroperitoneal 
lymph nodes 
3A: confined to the pelvis 
3B: metastasis to the peritoneal cavity but not >2cm mass 
3C: metastasis to the peritoneal cavity hut >2cm mass (this is the 
most common stage of diagnosis) 
Stage 4: metastasis into other distant organs 
Upon histological analysis of the excised tumor, epithelial ovarian cancer 
is subtyped to mucinous, serous, endometrioid, clear cell, transitional, 
small cell, malignant milled mesodermal, and unclassified (1). 
Symptoms 
Most of the time, patients are asymptomatic until the advanced stages are 
reached. In advanced stages, there is often abdominal fullness and pain 
(5, 9), urinary frequency, abnormal vaginal bleeding and pelvic pressure. 
Diagnosis 
A physical exam including a pelvic and abdominal exam should be done 
to detect any masses. Pleural effusions may be noted by decreased breath 
sounds and lymph nodes should be examined for any palpable masses. 
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CA-125 is often used to monitor and assess response to therapy, but 
should not be used as a diagnostic tool in women who are at low 1isk or 
asymptomatic (9). 80-85% of patients with advanced ovarian cancer have 
elevated CA· 125 (3). A complete blood count and an abnormal metabolic 
panel may be used as an indicator for epithelial ovarian cancer. 
Unfortunately, there is no definitive test for early diagnosis. Imaging 
techniques such as ultrasound is most commonly used to detect ovarian 
masses with ascites or free pelvic fluid. A chest radiograph is sometimes 
performed to detect the presence of nodules. A CT scan often shows a 
pelvic or abdominal mass (9).  
Other conditions causing similar symptoms 
Tuba-ovarian abscess or other infections such as appendicitis may 
present with similar symptoms. An elevated CA-125 or the presence of 
ascites may be detected in patients with Iiver disease. In addition, several 
other tumors such as borderline, malignant and nonmalignant tumors 
may also have similar symptoms to epithelial ovarian tumors. 
Treatment 
A laparotomy must be performed and the tumor staged. Maximum 
cytoreductive surgery is often essential for a better prognosis if cancer is 
found. Peritoneal washings should be performed and typed. Also, total 
abdominal hysterectomy is favorable as well as samples from the 
diaphragm to detect any metastasis (9). Adjuvant chemotherapy is 
standard in treating ovarian cancer patients. Standard chemotherapeutic 
agents used include a platinum agent such as cisplatin and taxanes such 
as paclitaxel. For patients that develop recurrent disease, several other 
drugs may be used but are only beneficial in 10-25% of the cases and are 
not curative (9). 
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Follow-up 
Patients should be referred to a gynecologic oncologist if there is a high 
likelihood of ovarian cancer. If diagnosed at early stages. the prognosis is 
much better. In fact, the 5-year survival rate at stage I is 90% whereas at 
advanced stages, it is about 20%. CA-125 should be used to monitor the 
patient on a regular basis every 3 months. Most reoccurrences of cancer 
occur during the first 2 years after treatment (9). 
F. VIRILIZING OVARIAN TUMORS 
This type of ovarian tumor is extremely rare. In fact, it accounts for about 
0.5% of all primary ovarian neoplasms. This type of tumor may occur at 
any age but mostly in the 2nd and 3rd decade of life. The hallmark of this 
tumor type is the production of androgenic steroid hormones. There arc 
several substances that are released by this tumor that may often be used 
as markers (9). In the pediatric and adolescent population, the presence 
o f  a virilizing tumor should be taken into consideration when prepubertal 
girls present to the clinic with precocious puberty. This tumor develops
 from the cells that surround the oocytes ( cumulus cells which are 
composed of granulosa cells). This tumor may be benign or malignant 
but is almost always firm, solid and have a smooth surface. Most of these 
tumors have low grade histology (9).  
Risk factors 
There are no known risk factors to date (9). 
Subtypes of v irilizing ovarian tumors 
All epithelial ovarian tumors should be removed and staged after 
excision using the International Federation of Gynecological Oncologists 
(FIGO). 
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Stage 1: tumor is confined to the ovaries 
1A: tumor growth is limited to one ovary without any malignant 
ascites 
1B: tumor growth is limited to two ovaries without any malignant 
ascites 
1 C: tumor or stage 1A or l B but with ascites or ruptured capsules 
Stage 2: tumor has spread to the pelvis 
2A: metastasis to the fallopian tubes or uterus
 2B: both ovaries affected and extended to the pelvis 
2C: a tumor of stage 2A or 2B but with ascites 
Stage 3: tumor seeds in the abdominal cavity or retroperitoneal 
lymph nodes 
3A: confined to the pelvis 
38: metastasis to the peritoneal cavity but not >2cm mass 
3C: metastasis to the peritoneal cavity but >2cm mass (this is the 
most common stage of diagnosis) 
Stage 4: metastasis into other distant organs 
There are mainly three subtypes of virilizing ovarian tumors 
• Sertoli-stromal cell tumors: These tumors may appear as well, 
poor or intermediate in differentiation.
• Gynandroblastoma
• Steroid (lipid) cell tumors: These include stromal luteoma, lydig 
cell tumor or unclassified. 
Symptoms 
The chief complaint is usually abdominal pain and an increase in  
abdominal girth. 
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Diagnosis 
There are certain findings during the physical exam that may help in the 
diagnosis of virilizing ovarian tumor such as a palpable adnexal mass, 
breast atrophy, hirsutism, deep voice, male pattern baldness and acne on 
the face or back. Certain lab tests such as inhibin, testosterone, AFP, 
DHEA . 17-hyclroxyprogesterone and androstenedione may be performed 
to help confirm the diagnosis. A pelvic ultrasound and a CT scan of the 
chest and abdomen are also preferable (9). 
Other conditions causing similar symptoms 
PCOS and Cushing syndrome often present with similar symptoms and 
lab results. Thus, it is necessary to eliminate any suspicion regarding the 
presence of a virilizing tumor. Steroid use may also cause similar lab 
results (9). 
T1·eatment 
Surgery is the main mode of treatment. Chemotherapy is often used to 
treat metastatic disease such as cisplatin and bleomycin (9). 
Follow-up 
Patients will need to visit a gynecologist every 2-4 weeks and a routine 
physical examination as well as testosterone levels every 2-3 months 
afterwards (9). 
RECENT ADVANCES IN TUMOR BIOMARKERS 
There have been several reports regarding potential new ovarian tumor 
diagnostic markers. One of the most researched in the literature is 
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Lysophosphatidic acid (LPA) receptor. LPA receptors are G-protein 
coupled receptors. Two receptor subtypes, namely LPA 2 and 3 have 
been shown to be over expressed in most ovarian cancer cells. There are 
several studies unde1way trying to decipher the role of LPA receptors in 
ovarian tumor progression and are showing promise to its use (27). 
OTHER CONCERNS 
Due to the rigorous treatment measures and chemotherapy, adolescents 
often struggle with depression and poor body image even after the tumor 
has been removed. Thus, it is of utmost impo1tance to take into account 
the psychological impact of the presence and treatment of ovarian 
rumors. In addition, fertility issues should be discussed extensively with 
the adolescent as well as their parents before any surgery is performed. It 
has been previously reported that there is a 15% decrease in fertility in 
survivors of pediatric gynecological cancers (28 ). 
SUMMARY OF LAB TESTS HELPFUL TO THE DIAGNOSIS 
OF OVARIAN CANCERS 
CA 125: usually elevated in epithelial tumors, and rarely in teratomas. It 
should not be used in asymptomatic patients 
AFP: usually elevated in germ cell tumors, embryonic carcinoma, 
endodermal tumors and rarely but may be seen in polyembryoma and 
immature teratoma. 
HCG: usually found in patients with choriocarcinoma, embryonic 
and germ cellrumors, and rarely in dysgerminoma 
Carcinoembryonic antigen and LDH: this is usually seen in germ cell 
tumors and dysgerminoma 
Estradiol: thecomas and adult granulose cell rumors 
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CONCLUSION 
Ovarian tumors are uncommon in the child and adolescent population, 
but given that cancer is a leading cause of death even in this age group it 
is important for the general practice physician to be aware of the signs 
and symptoms. These can include abdominal pain, increased abdominal 
girth, a palpable mass on pelvic or abdominal exam, nausea and 
vomiting, decreased appetite, weight loss, constipation, back pain. leg 
cramps, dyspareunia, urinary symptoms, abnormal uterine bleeding, and 
ascites, to name a few. The types of gynecological tumors seen in adults 
are also seen in children except in differing frequencies. The most 
common type of ovarian tumor in children is the germ cell tumor, of 
which there are several subtypes including dermoid cysts, 
dysgerminoma, yolk sac tumor, immature teratomas, and embryonal 
carcinomas. Each requires different laboratory workups and equally 
varied treatment plans. Functional cysts are typically benign in nature 
and can resolve on their own. Their etiology depends on the stage of the 
female cycle in which they occur. Other benign ovarian rumors such as 
endometriomas, cystic teratomas, and epithelial tumors along with 
borderline ovarian tumors, which may progress to a malignant stage, are 
rare in children and adolescents. Given the low probability of malignancy 
of these rumors, but poor prognosis if discovered at an advanced stage, it 
is important for the general practitioner and pediatrician to keep a high 
level of suspicion. Given the symptoms for ovarian tumors are common 
complaints seen daily in the outpatient setting, these can be difficult to 
differentiate from more common diagnoses, but is the reason to keep in 
mind other aspects of the child and their overall growth and 
development. Body image and fertility are significant issues to the 
adolescent female, therefore side effects as well as benefits of treatment 
sbould be given adequate discussion with the physician, parents and 
patient prior to initiation of treatment. 
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